ALDH3A2

ALDH3A2 encodes fatty aldehyde dehydrogenase (FALDH), a microsomal enzyme that catalyzes the NAD⁺-dependent oxidation of long-chain aliphatic aldehydes—including lipid peroxidation-derived 4-hydroxynonenal (4-HNE) and intermediates of sphingolipid/fatty alcohol metabolism—to their corresponding fatty acids. Loss-of-function mutations in the catalytic domain, substrate-gating region, or C-terminal α-helix profoundly reduce enzymatic activity in patient fibroblasts and expression systems, causing Sjögren–Larsson syndrome characterized by ichthyosis and defective myelination (PMID:15931689, PMID:34082469). In skin, ALDH3A2 is the predominant fatty aldehyde dehydrogenase in undifferentiated keratinocytes; its knockout leads to impaired long-chain base metabolism, keratinocyte hyperproliferation, oxidative stress gene upregulation, and delayed barrier recovery (PMID:27053112). ALDH3A2 also protects against lipid peroxidation–driven damage: it detoxifies 4-HNE to preserve insulin receptor substrate signaling in adipocytes (PMID:18174527), and its loss sensitizes cells to ferroptosis by disrupting lipid and glutathione homeostasis (PMID:37247796).

1. 1997 High

   Defining the gene structure and transcriptional regulation of ALDH3A2 established it as a widely expressed, alternatively spliced gene with a TATA-less, GC-rich promoter, explaining how multiple FALDH isoforms with potentially distinct membrane-binding properties arise.

   Evidence Northern blot, S1 nuclease protection, primer extension, and in vitro transcription assays using HeLa nuclear extracts

   PMID:9027499

   Open questions at the time

   • Functional consequence of the alternatively spliced exon on membrane anchoring was not directly tested
   • Transcription factor identity at the GC-rich promoter elements was not resolved
2. 2005 High

   Systematic mutation–activity correlation across >72 ALDH3A2 mutations demonstrated that missense changes throughout the catalytic domain profoundly reduce FALDH enzymatic activity, establishing the genotype–phenotype basis of Sjögren–Larsson syndrome.

   Evidence Expression studies in cultured patient fibroblasts with enzymatic activity assays and mutation analysis

   PMID:15241804 PMID:15931689

   Open questions at the time

   • No crystal structure to explain how individual mutations alter catalysis
   • Residual activity thresholds predicting disease severity were not defined
3. 2006 Medium

   Identification of PPAR-dependent transcriptional induction of ALDH3A2 by bezafibrate revealed a druggable regulatory axis and suggested a pharmacological strategy to boost residual FALDH activity in patients.

   Evidence FALDH enzymatic activity and mRNA measurements in fibroblasts treated with bezafibrate

   PMID:16837225

   Open questions at the time

   • Direct PPAR binding to the ALDH3A2 promoter was not shown
   • In vivo efficacy and clinical relevance of bezafibrate-mediated induction were not established
4. 2008 High

   Demonstrating that FALDH detoxifies 4-HNE and thereby preserves IRS-1/IRS-2 from adduct formation expanded ALDH3A2 function beyond lipid metabolism to insulin signaling protection.

   Evidence Adenoviral FALDH overexpression in 3T3-L1 adipocytes with co-immunoprecipitation of HNE adducts, insulin-stimulated IRS-1 phosphorylation, PI3K activity, PKB activity, and glucose uptake assays

   PMID:18174527

   Open questions at the time

   • Endogenous FALDH loss-of-function effect on insulin signaling in vivo was not tested
   • Relative contribution of FALDH vs. other 4-HNE-metabolizing enzymes in adipocytes was not quantified
5. 2016 High

   Aldh3a2 knockout mice revealed that FALDH is the dominant aldehyde-oxidizing enzyme in undifferentiated keratinocytes and that its loss causes hyperproliferation, impaired sphingolipid metabolism, and defective skin barrier—recapitulating key features of Sjögren–Larsson syndrome.

   Evidence Aldh3a2 knockout mice with enzymatic activity assays, gene expression profiling, histology, and transepidermal water loss measurement

   PMID:27053112

   Open questions at the time

   • CNS myelination defect was not characterized in this model
   • Identity of accumulating toxic aldehyde species in skin was not fully resolved
6. 2018 Medium

   Placing ALDH3A2 downstream of Activin/Smad2–Wnt/β-catenin–FOXH1 signaling during mesendoderm differentiation revealed an unexpected developmental role, where ALDH3A2 knockdown severely attenuated differentiation of human embryonic stem cells.

   Evidence ChIP-seq, knockdown experiments, differentiation assays, and Western blot for H3K27me3/EZH2 in hESCs

   PMID:30282636

   Open questions at the time

   • Mechanism by which FALDH enzymatic activity promotes mesendoderm differentiation is unknown
   • Whether aldehyde detoxification or a non-canonical function drives the differentiation phenotype was not resolved
7. 2021 Medium

   Extending structure–function mapping to the C-terminal α-helix and substrate-gating region refined understanding of FALDH domain architecture and confirmed that mutations outside the catalytic center also abolish activity.

   Evidence Mammalian expression of mutant constructs with enzymatic activity assays and patient fibroblast analysis

   PMID:34082469

   Open questions at the time

   • No high-resolution structural data to model substrate access or gating mechanism
   • Protein stability vs. catalytic defect was not distinguished for all mutants
8. 2023 Medium

   ALDH3A2 knockout in ovarian cancer cells elevated ferroptosis sensitivity while overexpression attenuated it, linking FALDH's aldehyde-detoxifying function to protection against lipid peroxidation-dependent cell death.

   Evidence CRISPR knockout and overexpression with ferroptosis sensitivity assays and RNA-seq pathway analysis in ovarian cancer cells

   PMID:37247796

   Open questions at the time

   • Specific lipid aldehyde substrates driving ferroptosis sensitization were not identified
   • Whether ferroptosis protection is a general or cancer cell-type-specific function is unknown

• The three-dimensional structure of FALDH, the identity of its full aldehyde substrate repertoire in vivo, and the mechanism by which its enzymatic activity supports mesendoderm differentiation and CNS myelination remain unresolved.
• No crystal or cryo-EM structure of FALDH
• Substrate specificity in different tissues has not been systematically profiled
• Mechanism linking FALDH loss to myelination failure in the CNS is unknown